Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


Articles published in J Neurol

Retrieve available abstracts of 164 articles:
HTML format
Text format



Single Articles


    April 2018
  1. RASUL T, Frederiksen JL
    Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis.
    J Neurol. 2018 Apr 26. pii: 10.1007/s00415-018-8869.
    PubMed     Text format     Abstract available


  2. HUHN K, Bayas A, Doerck S, Frank B, et al
    Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    J Neurol. 2018 Apr 25. pii: 10.1007/s00415-018-8871.
    PubMed     Text format     Abstract available


  3. TAVAZZI E, Bergsland N, Cattaneo D, Gervasoni E, et al
    Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.
    J Neurol. 2018 Apr 7. pii: 10.1007/s00415-018-8859.
    PubMed     Text format     Abstract available


    March 2018
  4. COGHE G, Corona F, Marongiu E, Fenu G, et al
    Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.
    J Neurol. 2018 Mar 24. pii: 10.1007/s00415-018-8836.
    PubMed     Text format     Abstract available


  5. NAKKEN O, Lindstrom JC, Holmoy T
    Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway.
    J Neurol. 2018 Mar 21. pii: 10.1007/s00415-018-8832.
    PubMed     Text format     Abstract available


  6. CERONIE B, Jacobs BM, Baker D, Dubuisson N, et al
    Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    J Neurol. 2018 Mar 17. pii: 10.1007/s00415-018-8830.
    PubMed     Text format     Abstract available


  7. LANZILLO R, Prosperini L, Gasperini C, Moccia M, et al
    A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
    J Neurol. 2018 Mar 16. pii: 10.1007/s00415-018-8831.
    PubMed     Text format     Abstract available


  8. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
    J Neurol. 2018 Mar 12. pii: 10.1007/s00415-018-8813.
    PubMed     Text format     Abstract available


  9. DEVONSHIRE V, Phillips R, Wass H, Da Roza G, et al
    Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    J Neurol. 2018 Mar 10. pii: 10.1007/s00415-018-8822.
    PubMed     Text format     Abstract available


  10. HOTTENROTT T, Schorb E, Fritsch K, Dersch R, et al
    The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
    J Neurol. 2018 Mar 6. pii: 10.1007/s00415-018-8779.
    PubMed     Text format     Abstract available


  11. LOREFICE L, Fenu G, Pitzalis R, Scalas G, et al
    Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.
    J Neurol. 2018 Mar 5. pii: 10.1007/s00415-018-8811.
    PubMed     Text format     Abstract available


    February 2018
  12. BROICHER SD, Filli L, Geisseler O, Germann N, et al
    Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8796.
    PubMed     Text format     Abstract available


  13. VAN DER VUURST DE VRIES RM, Mescheriakova JY, Runia TF, Siepman TAM, et al
    Smoking at time of CIS increases the risk of clinically definite multiple sclerosis.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8780.
    PubMed     Text format     Abstract available


  14. BELL JS, Spencer JI, Yates RL, DeLuca GC, et al
    The cortical blood-brain barrier in multiple sclerosis: a gateway to progression?
    J Neurol. 2018 Feb 13. pii: 10.1007/s00415-017-8727.
    PubMed     Text format    


  15. ESPOSITO F, Ferre L, Clarelli F, Rocca MA, et al
    Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    J Neurol. 2018 Feb 12. pii: 10.1007/s00415-018-8791.
    PubMed     Text format     Abstract available


  16. ARNETH B
    Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections.
    J Neurol. 2018 Feb 8. pii: 10.1007/s00415-018-8783.
    PubMed     Text format     Abstract available


  17. SOLARO C, Cella M, Signori A, Martinelli V, et al
    Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.
    J Neurol. 2018 Feb 5. pii: 10.1007/s00415-018-8758.
    PubMed     Text format     Abstract available


  18. KALRON A, Allali G, Achiron A
    Cerebellum and cognition in multiple sclerosis: the fall status matters.
    J Neurol. 2018 Feb 2. pii: 10.1007/s00415-018-8774.
    PubMed     Text format     Abstract available


  19. WINDER K, Linker RA, Seifert F, Deutsch M, et al
    Insular multiple sclerosis lesions are associated with erectile dysfunction.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8763.
    PubMed     Text format     Abstract available


  20. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8764.
    PubMed     Text format     Abstract available


    January 2018
  21. VOGRIG A, Joubert B, Ducray F, Thomas L, et al
    Glioblastoma as differential diagnosis of autoimmune encephalitis.
    J Neurol. 2018 Jan 30. pii: 10.1007/s00415-018-8767.
    PubMed     Text format     Abstract available


  22. GILHUS NE, Romi F, Hong Y, Skeie GO, et al
    Myasthenia gravis and infectious disease.
    J Neurol. 2018 Jan 25. pii: 10.1007/s00415-018-8751.
    PubMed     Text format     Abstract available


  23. FIENE M, Rufener KS, Kuehne M, Matzke M, et al
    Electrophysiological and behavioral effects of frontal transcranial direct current stimulation on cognitive fatigue in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8754.
    PubMed     Text format     Abstract available


  24. LEAVITT VM, Tosto G, Riley CS
    Cognitive phenotypes in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8747.
    PubMed     Text format     Abstract available


  25. DI GREGORIO M, Gaetani L, Eusebi P, Floridi P, et al
    Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    J Neurol. 2018 Jan 11. pii: 10.1007/s00415-017-8726.
    PubMed     Text format     Abstract available


    December 2017
  26. FRAU J, Villar LM, Sardu C, Secci MA, et al
    Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8716.
    PubMed     Text format     Abstract available


  27. BRENTON JN, Schreiner T, Karoscik K, Richter M, et al
    Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis.
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8715.
    PubMed     Text format     Abstract available


  28. SHRIBMAN S, Hasan H, Hadavi S, Giovannoni G, et al
    The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis.
    J Neurol. 2017 Dec 4. pii: 10.1007/s00415-017-8690.
    PubMed     Text format     Abstract available


    November 2017
  29. THALER C, Faizy TD, Sedlacik J, Bester M, et al
    The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8683.
    PubMed     Text format     Abstract available


  30. CONRADSSON D, Ytterberg C, von Koch L, Johansson S, et al
    Changes in disability in people with multiple sclerosis: a 10-year prospective study.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8676.
    PubMed     Text format     Abstract available


  31. ELIASDOTTIR O, Hildeman A, Longfils M, Nerman O, et al
    A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8665.
    PubMed     Text format     Abstract available


  32. RUPRECHT K, Wildemann B, Jarius S
    Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.
    J Neurol. 2017 Nov 2. doi: 10.1007/s00415-017-8656.
    PubMed     Text format     Abstract available


    October 2017
  33. COMI G, Patti F, Rocca MA, Mattioli FC, et al
    Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8642.
    PubMed     Text format     Abstract available


  34. PARDO G, Jones DE
    Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8633.
    PubMed     Text format     Abstract available


  35. ABBOUD H, Rossman I, Mealy MA, Hill E, et al
    Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.
    J Neurol. 2017 Oct 3. doi: 10.1007/s00415-017-8627.
    PubMed     Text format     Abstract available


    September 2017
  36. WANG L, Zhang S, Xi J, Li W, et al
    Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2017 Sep 18. doi: 10.1007/s00415-017-8616.
    PubMed     Text format     Abstract available


  37. LOREFICE L, Coghe G, Fenu G, Porta M, et al
    'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.
    J Neurol. 2017 Sep 11. doi: 10.1007/s00415-017-8612.
    PubMed     Text format     Abstract available


  38. PARDO G, Jones DE
    The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Sep 6. doi: 10.1007/s00415-017-8594.
    PubMed     Text format     Abstract available


    August 2017
  39. LATTANZI S, Danni M, Taffi R, Cerqua R, et al
    Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    J Neurol. 2017 Aug 22. doi: 10.1007/s00415-017-8595.
    PubMed     Text format     Abstract available


  40. HRASTELJ J, Robertson N
    Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8584.
    PubMed     Text format    


  41. FINKE C, Bartels F, Lutt A, Pruss H, et al
    High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8582.
    PubMed     Text format     Abstract available


    July 2017
  42. EICHINGER P, Wiestler H, Zhang H, Biberacher V, et al
    A novel imaging technique for better detecting new lesions in multiple sclerosis.
    J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8576.
    PubMed     Text format     Abstract available


  43. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Erratum to: Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jul 10. doi: 10.1007/s00415-017-8556.
    PubMed     Text format    


    June 2017
  44. CASEY JP, Hirouchi T, Hisatsune C, Lynch B, et al
    A novel gain-of-function mutation in the ITPR1 suppressor domain causes spinocerebellar ataxia with altered Ca2+ signal patterns.
    J Neurol. 2017 Jun 15. doi: 10.1007/s00415-017-8545.
    PubMed     Text format     Abstract available


  45. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jun 12. doi: 10.1007/s00415-017-8541.
    PubMed     Text format     Abstract available


  46. HAGSTROM IT, Schneider R, Bellenberg B, Salmen A, et al
    Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.
    J Neurol. 2017 Jun 9. doi: 10.1007/s00415-017-8537.
    PubMed     Text format     Abstract available


    May 2017
  47. BRITZE J, Pihl-Jensen G, Frederiksen JL
    Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.
    J Neurol. 2017 May 31. doi: 10.1007/s00415-017-8531.
    PubMed     Text format     Abstract available


  48. DIBLEY L, Coggrave M, McClurg D, Woodward S, et al
    "It's just horrible": a qualitative study of patients' and carers' experiences of bowel dysfunction in multiple sclerosis.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8527.
    PubMed     Text format     Abstract available


  49. RATH J, Mauritz M, Zulehner G, Hilger E, et al
    Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8518.
    PubMed     Text format     Abstract available


  50. RIVIERE E, Cohen Aubart F, Maisonobe T, Maurier F, et al
    Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study.
    J Neurol. 2017 May 23. doi: 10.1007/s00415-017-8519.
    PubMed     Text format     Abstract available


  51. FOULON S, Maura G, Dalichampt M, Alla F, et al
    Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8513.
    PubMed     Text format     Abstract available


  52. CORDTS I, Bodart N, Hartmann K, Karagiorgou K, et al
    Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8514.
    PubMed     Text format     Abstract available


  53. LATTANZI S, Cagnetti C, Danni M, Provinciali L, et al
    Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    J Neurol. 2017 May 10. doi: 10.1007/s00415-017-8505.
    PubMed     Text format     Abstract available


    April 2017
  54. HARDING K, Tilling K, MacIver C, Willis M, et al
    Seasonal variation in multiple sclerosis relapse.
    J Neurol. 2017 Apr 19. doi: 10.1007/s00415-017-8485.
    PubMed     Text format     Abstract available


  55. SARTORI A, Abdoli M, Freedman MS
    Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    J Neurol. 2017 Apr 17. doi: 10.1007/s00415-017-8487.
    PubMed     Text format     Abstract available


  56. HAINLINE C, Rizzo JR, Hudson TE, Dai W, et al
    Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.
    J Neurol. 2017 Apr 7. doi: 10.1007/s00415-017-8484.
    PubMed     Text format     Abstract available


  57. CHOI HA, Lee MJ, Chung CS
    Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis.
    J Neurol. 2017;264:724-732.
    PubMed     Text format     Abstract available


  58. BARTOLINI L, Muscal E
    Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey.
    J Neurol. 2017;264:647-653.
    PubMed     Text format     Abstract available


    March 2017
  59. HONG Y, Skeie GO, Zisimopoulou P, Karagiorgou K, et al
    Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.
    J Neurol. 2017 Mar 31. doi: 10.1007/s00415-017-8478.
    PubMed     Text format     Abstract available


  60. PREZIOSA P, Martinelli V, Ferre L, Guaschino C, et al
    Moyamoya disease mimicking the first attack of multiple sclerosis.
    J Neurol. 2017 Mar 17. doi: 10.1007/s00415-017-8458.
    PubMed     Text format    


  61. MCLAUCHLAN D, Robertson NP
    B cell treatments for multiple sclerosis.
    J Neurol. 2017 Mar 4. doi: 10.1007/s00415-017-8442.
    PubMed     Text format    


  62. ROODBOL J, de Wit MY, van den Berg B, Kahlmann V, et al
    Diagnosis of Guillain-Barre syndrome in children and validation of the Brighton criteria.
    J Neurol. 2017 Mar 1. doi: 10.1007/s00415-017-8429.
    PubMed     Text format     Abstract available


  63. KHAN F, Amatya B, Galea MP, Gonzenbach R, et al
    Neurorehabilitation: applied neuroplasticity.
    J Neurol. 2017;264:603-615.
    PubMed     Text format     Abstract available


    February 2017
  64. DULAU C, Deloire M, Diaz H, Saubusse A, et al
    Social cognition according to cognitive impairment in different clinical phenotypes of multiple sclerosis.
    J Neurol. 2017 Feb 20. doi: 10.1007/s00415-017-8417.
    PubMed     Text format     Abstract available


  65. NIJ BIJVANK JA, Balk LJ, Tan HS, Uitdehaag BM, et al
    A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer.
    J Neurol. 2017 Feb 13. doi: 10.1007/s00415-017-8412.
    PubMed     Text format    


  66. MALONEY E, Molloy A, Al Hussona M, O'Donnell L, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    J Neurol. 2017;264:401-403.
    PubMed     Text format    


    January 2017
  67. TAYLOR CJ, Hirsch NP, Kullmann DM, Howard RS, et al
    Changes in the severity and subtype of Guillain-Barre syndrome admitted to a specialist Neuromedical ICU over a 25 year period.
    J Neurol. 2017 Jan 16. doi: 10.1007/s00415-016-8380.
    PubMed     Text format     Abstract available


  68. BIANCHI A, Bartolini E, Melani F, Guerrini R, et al
    Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies.
    J Neurol. 2017;264:179-181.
    PubMed     Text format    


    December 2016
  69. HYNCICOVA E, Vyhnalek M, Kalina A, Martinkovic L, et al
    Cognitive impairment and structural brain changes in patients with clinically isolated syndrome at high risk for multiple sclerosis.
    J Neurol. 2016 Dec 27. doi: 10.1007/s00415-016-8368.
    PubMed     Text format     Abstract available


  70. JARIUS S, Eichhorn P, Franciotta D, Petereit HF, et al
    The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature.
    J Neurol. 2016 Dec 22. doi: 10.1007/s00415-016-8360.
    PubMed     Text format     Abstract available


  71. JONES LA, Robertson NP
    An update on treatments in myasthenia gravis.
    J Neurol. 2016 Dec 20. doi: 10.1007/s00415-016-8359.
    PubMed     Text format    


  72. BRECKWOLDT MO, Gradl J, Hahnel S, Hielscher T, et al
    Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  73. GIORLI E, Franciotta D, Beronio A, Amodeo C, et al
    Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD.
    J Neurol. 2016;263:2549-2551.
    PubMed     Text format    


  74. HUSS AM, Halbgebauer S, Ockl P, Trebst C, et al
    Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
    J Neurol. 2016;263:2499-2504.
    PubMed     Text format     Abstract available


  75. HUANG Q, Wu Y, Qin R, Wei X, et al
    Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.
    J Neurol. 2016;263:2446-2455.
    PubMed     Text format     Abstract available


    November 2016
  76. BLOCK VJ, Lizee A, Crabtree-Hartman E, Bevan CJ, et al
    Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  77. BLASCO MR, Ramos A, Malo CG, Garcia-Merino A, et al
    Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  78. SCHWARTZBACH CJ, Grove RA, Brown R, Tompson D, et al
    Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  79. PROSPERINI L, Sacca F, Cordioli C, Cortese A, et al
    Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  80. KOSMIDOU M, Katsanos AH, Katsanos KH, Kyritsis AP, et al
    Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  81. HAVLA J, Kumpfel T, Schinner R, Spadaro M, et al
    Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  82. DRESSLER D, Bhidayasiri R, Bohlega S, Chahidi A, et al
    Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  83. PAKPOOR J, Goldacre R, Goldacre MJ
    Low testosterone and myasthenia gravis in males: a national record-linkage study.
    J Neurol. 2016.
    PubMed     Text format    


  84. VAN GEEST Q, Westerik B, van der Werf YD, Geurts JJ, et al
    The role of sleep on cognition and functional connectivity in patients with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  85. THORMANN A, Magyari M, Koch-Henriksen N, Laursen B, et al
    Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  86. PIETRZAK K, Grzybowski A, Kaczmarczyk J
    Georges Guillain (1876-1961).
    J Neurol. 2016;263:2148-9.
    PubMed     Text format    


  87. ABSINTA M, Reich DS, Filippi M
    Spring cleaning: time to rethink imaging research lines in MS?
    J Neurol. 2016;263:1893-902.
    PubMed     Text format     Abstract available


    September 2016
  88. OWEN PICKRELL W, Robertson NP
    Stem cell treatment for multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  89. HEINE J, Ly LT, Lieker I, Slowinski T, et al
    Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  90. MAILAND MT, Frederiksen JL
    Vaccines and multiple sclerosis: a systematic review.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  91. MAILLART E, Papeix C, Mellerio C, Bertrand A, et al
    Extensive and severe CNS demyelination associated with golimumab therapy.
    J Neurol. 2016;263:1869-71.
    PubMed     Text format    


  92. LOZERON P, Ribrag V, Adams D, Brisset M, et al
    Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?
    J Neurol. 2016;263:1761-70.
    PubMed     Text format     Abstract available


  93. ANNOVAZZI P, Capobianco M, Moiola L, Patti F, et al
    Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    J Neurol. 2016;263:1727-35.
    PubMed     Text format     Abstract available


    August 2016
  94. EL AYOUBI NK, Ghassan S, Said M, Allam J, et al
    Retinal measures correlate with cognitive and physical disability in early multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  95. MOBERG JY, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  96. SCHIRMER L, Worthington V, Solloch U, Loleit V, et al
    Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barre syndrome.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  97. ZURAWSKI J, Flinn A, Sklover L, Sloane JA, et al
    Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
    J Neurol. 2016;263:1511-7.
    PubMed     Text format     Abstract available


    July 2016
  98. ZIEMSSEN T, Phillips G, Shah R, Mathias A, et al
    Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ).
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  99. ZHOU H, Zhao S, Yin D, Chen X, et al
    Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
    J Neurol. 2016;263:1382-9.
    PubMed     Text format     Abstract available


  100. JEONG IH, Kim HJ, Kim NH, Jeong KS, et al
    Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
    J Neurol. 2016;263:1343-8.
    PubMed     Text format     Abstract available


  101. BALK LJ, Cruz-Herranz A, Albrecht P, Arnow S, et al
    Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
    J Neurol. 2016;263:1323-31.
    PubMed     Text format     Abstract available


  102. HAVRDOVA E, Belova A, Goloborodko A, Tisserant A, et al
    Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
    J Neurol. 2016;263:1287-95.
    PubMed     Text format     Abstract available


    June 2016
  103. BERCIANO J, Sedano MJ, Pelayo-Negro AL, Garcia A, et al
    Proximal nerve lesions in early Guillain-Barre syndrome: implications for pathogenesis and disease classification.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  104. PRIETO-MORIN C, Ayrignac X, Ellie E, Tournier-Lasserve E, et al
    CSF1R-related leukoencephalopathy mimicking primary progressive multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  105. D'AMICO E, Leone C, Zanghi A, Fermo SL, et al
    Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  106. KALRON A, Givon U
    Gait characteristics according to pyramidal, sensory and cerebellar EDSS subcategories in people with multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  107. NEWSOME SD, Kieseier BC, Arnold DL, Shang S, et al
    Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  108. HOSOKAWA T, Nakajima H, Unoda K, Yamane K, et al
    Serial electrophysiological findings in Guillain-Barre syndrome not fulfilling AIDP or AMAN criteria.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  109. JONGEN PJ, Stavrakaki I, Voet B, Hoogervorst E, et al
    Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  110. MICLEA A, Leussink VI, Hartung HP, Gold R, et al
    Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  111. IAFFALDANO P, Viterbo RG, Trojano M
    Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  112. BRIER MR, Day GS, Snyder AZ, Tanenbaum AB, et al
    N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI.
    J Neurol. 2016;263:1083-91.
    PubMed     Text format     Abstract available


  113. GRIMM A, Vittore D, Schubert V, Rasenack M, et al
    Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
    J Neurol. 2016;263:1074-82.
    PubMed     Text format     Abstract available


    May 2016
  114. BEER A, Biberacher V, Schmidt P, Righart R, et al
    Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  115. SCHIPPLING S, O'Connor P, Knappertz V, Pohl C, et al
    Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  116. AMANN M, Pezold S, Naegelin Y, Fundana K, et al
    Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  117. DAVION JB, Cambron M, Duhin E, Chouraki A, et al
    Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  118. SEPULVEDA M, Armangue T, Martinez-Hernandez E, Arrambide G, et al
    Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  119. VINJAM MR, Shanmugarajah P, Ford HL
    Ophthalmoplegia heralding the onset of anti-amphiphysin related paraneoplastic stiff person syndrome.
    J Neurol. 2016;263:1017-8.
    PubMed     Text format    


    April 2016
  120. MCCARTHY C, Thorpe J
    Some recent advances in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  121. GAETANI L, Mignarri A, Di Gregorio M, Sarchielli P, et al
    Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion.
    J Neurol. 2016.
    PubMed     Text format    


  122. DE KOUCHKOVSKY I, Fieremans E, Fleysher L, Herbert J, et al
    Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  123. GROTHE M, Lotze M, Langner S, Dressel A, et al
    The role of global and regional gray matter volume decrease in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  124. SANDROFF BM, Schwartz CE, DeLuca J
    Measurement and maintenance of reserve in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  125. FAISSNER S, Nikolayczik J, Chan A, Hellwig K, et al
    Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  126. TALLANTYRE EC, Robertson NP
    Continuous evolution of magnetic resonance imaging in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  127. MATRICARDI S, Patrini M, Freri E, Ragona F, et al
    Cognitive and neuropsychological evolution in children with anti-NMDAR encephalitis.
    J Neurol. 2016;263:765-71.
    PubMed     Text format     Abstract available


    March 2016
  128. HALBGEBAUER S, Huss A, Buttmann M, Steinacker P, et al
    Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  129. RAGGI A, Leonardi M, Schiavolin S, Antozzi C, et al
    Validation of the MG-DIS: a disability assessment for myasthenia gravis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  130. HUSSAIN R, O'Leary S, Pacheco FM, Zacharias TE, et al
    Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
    J Neurol. 2016;263:606-10.
    PubMed     Text format     Abstract available


  131. FILIPPI M, Barker RA, Strupp M
    The neurology community mourns the passing of Dr. John F. Kurtzke.
    J Neurol. 2016;263:421.
    PubMed     Text format    


  132. AYZENBERG I, Schollhammer J, Hoepner R, Hellwig K, et al
    Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
    J Neurol. 2016;263:575-82.
    PubMed     Text format     Abstract available


    February 2016
  133. BUTTERWORTH SE, Ingram G, Robertson NP
    Advances in biomarker research in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format    


  134. BARNETT MH, McLeod JG, Hammond SR, Kurtzke JF, et al
    Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  135. ZIEMSSEN T, Calabrese P, Penner IK, Apfel R, et al
    QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naive patients, and previously treated patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  136. MELZER N, Ruck T, Fuhr P, Gold R, et al
    Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  137. LADWIG A, Dunkl V, Richter N, Schroeter M, et al
    Two cases of multiple sclerosis manifesting after in vitro fertilization procedures.
    J Neurol. 2016.
    PubMed     Text format    


  138. BARGAGLI AM, Colais P, Agabiti N, Mayer F, et al
    Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  139. MATAS E, Bau L, Martinez-Iniesta M, Romero-Pinel L, et al
    Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  140. ORTIZ-PEREZ S, Andorra M, Sanchez-Dalmau B, Torres-Torres R, et al
    Visual field impairment captures disease burden in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  141. PICCOLO L, Woodhall M, Tackley G, Jurynczyk M, et al
    Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    J Neurol. 2016;263:370-9.
    PubMed     Text format     Abstract available


  142. JEFFERY DR, Di Cantogno EV, Ritter S, Meier DP, et al
    The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.
    J Neurol. 2016;263:299-305.
    PubMed     Text format     Abstract available


    January 2016
  143. DOTY RL, Tourbier IA, Pham DL, Cuzzocreo JL, et al
    Taste dysfunction in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  144. JORDAN B, Kellner J, Jordan K, Bahre M, et al
    Thymic pathologies in myasthenia gravis: a preoperative assessment of CAT scan and nuclear based imaging.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  145. KIM G, Tauhid S, Dupuy SL, Tummala S, et al
    An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  146. BOVE R, McHenry A, Hellwig K, Houtchens M, et al
    Multiple sclerosis in men: management considerations.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  147. BAYSAL-KIRAC L, Tuzun E, Erdag E, Ulusoy C, et al
    Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


  148. ABKUR TM, Foran E, Kearney H, Harkin G, et al
    Neuromyelitis optica presenting as intractable vomiting and hyperCKaemia.
    J Neurol. 2016;263:171-3.
    PubMed     Text format    


  149. JURYNCZYK M, Weinshenker B, Akman-Demir G, Asgari N, et al
    Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.
    J Neurol. 2016;263:140-9.
    PubMed     Text format     Abstract available


  150. AZZOPARDI L, Cox AL, McCarthy CL, Jones JL, et al
    Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
    J Neurol. 2016;263:25-9.
    PubMed     Text format     Abstract available


    December 2015
  151. ZIEMSSEN T, Derfuss T, de Stefano N, Giovannoni G, et al
    Optimizing treatment success in multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  152. BINKS S, Vincent A, Palace J
    Myasthenia gravis: a clinical-immunological update.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  153. JORDAN B, Schilling S, Zierz S
    Switch to double positive late onset MuSK myasthenia gravis following thymomectomy in paraneoplastic AChR antibody positive myasthenia gravis.
    J Neurol. 2015.
    PubMed     Text format    


  154. KAPPOS L, Radue EW, Chin P, Ritter S, et al
    Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


  155. BRAUNE S, Lang M, Bergmann A
    Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  156. SALZER J, Lycke J, Wickstrom R, Naver H, et al
    Rituximab in paediatric onset multiple sclerosis: a case series.
    J Neurol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  157. KRUMBHOLZ M, Hofstadt-van Oy U, Angstwurm K, Kleiter I, et al
    Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75.
    J Neurol. 2015;262:1379-84.
    PubMed     Text format     Abstract available


  158. RICE CM, Kurian KM, Renowden S, Whiteway A, et al
    Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system.
    J Neurol. 2015;262:1354-9.
    PubMed     Text format     Abstract available


    March 2015
  159. KOIKE H, Akiyama K, Saito T, Sobue G, et al
    Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial.
    J Neurol. 2015;262:752-9.
    PubMed     Text format     Abstract available


  160. KIM SH, Hyun JW, Jeong IH, Joung A, et al
    Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.
    J Neurol. 2015;262:696-700.
    PubMed     Text format     Abstract available


    February 2015
  161. KAUFMAN M, Cree BA, De Seze J, Fox RJ, et al
    Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
    J Neurol. 2015;262:326-36.
    PubMed     Text format     Abstract available


    January 2015
  162. JONKMAN LE, Soriano AL, Amor S, Barkhof F, et al
    Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study.
    J Neurol. 2015;262:1074-80.
    PubMed     Text format     Abstract available


  163. LAUDA F, Fangerau T, Javaheripour-Otto K, Pinkhardt E, et al
    Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
    J Neurol. 2015;262:1055-7.
    PubMed     Text format    


    April 2014
  164. FILIPPI M
    MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment.
    J Neurol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: